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The enzyme cyclooxygenase, better known as COX 
metabolises Arachidonic Acid into various 
prostaglandins!. Until recently, it was believed that 
COX was a single enzyme. However, in 1989 a second 
isoform of COX was discovered' and named COX-2. 
COX-1 is constitutively expressed in almost all cells in 
the human body. It has a role in normal physiological 
functions such as vascular homeostasis, renal 
osmoregulation and cytoprotection in the stomach3 . In 
contrast, COX-2 is highly inducible and almost always 
absent in normal cell function. Elevated expression of 
COX-2 have been seen in arthritis, acute inflammation 
and has recently been recognised in epithelial 
malignancies such as colon carcinoma"-6 Non steroidal 
anti-inflammatory drugs (NSAIDs) form a drug group 
with anti-inflammatory, anti-pyretic and anti-
thrombotic properties. They work by inhibiting the 
activities of COX, hence prohibiting the synthesis of 
prostanoids'- Drugs that preferentially or selectively 
inhibit the activity of COX-2 such as nimesulide, 
meloxicam and NS 398 have been proven to have a low 
IC-50 (inhibitory concentration to reduce biosynthesis 
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by 50%) ratio for COX-2/COX-l as opposed to non 
selective COX inhibitors such as asprins. This means 
selective COX-2 drugs have less associated side effects as 
the activity of COX-1 still remains intact. The effects of 
NSAIDs on colonic diverticular disease are due to the 
non-selective inhibition of COX-1 , and consequently an 
inhibition of the mucosal-protective prostaglandins. 
This in turn can predispose to colonic bleeding, more 
commonly associated with coexistent colonic 
diverticular disease. 
Apoptosis or programmed cell death is a genetically 
controlled response for cells to commit suicide. The 
control of apoptosis is regulated by the bcl-2 gene9 • In 
many neoplastic conditions, abnormality of function or 
expression of this family of genes has been 
demonstrated. On a cellular level, cell blebbing, 
pyknosis and DNA fragmentation in an apoptotic cell 
can be observed. Recently, it has been found that the use 
of NSAIDs can induce apoptosis in some forms of 
carcinomas, such as colon and rectal carcinoma, as well 
as in pre-malignant conditions such as polyposis coli!o.l1. 
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Prostaglandins consist of a series of compounds 
collectively known as prostanoids. The compounds 
include both prostaglandins and thromboxanes. The 
generation of both prostaglandins and thromboxanes is 
initiated by the liberation of arachidonic acid from the 
cell membrane. Free arachidonic acid is converted by 
COX into prostaglandin H, (PGH,). This compound is 
further metabolised into various prostaglandins 
depending on cell type. In platelets, Thromboxane A, 
(TXA,) is produced while Prostaglandin E2 (PGE2) and 
Prostacyclin (PGI,) are produced in monocytes and 
endothelial cells respectivelyl'. The use of NSAIDs 
inhibits the activity COX and hence the production of 
prostaglandins and thromboxanes. 
bpreSSltlli1 @f COX·2 and l'ie@p~lClsms 
The expression of COX-2 in various types of neoplastic 
lesion is well recognised and documented. Elevated 
expression of COX-2 isoenzyme has been demonstrated 
in colon and rectal carcinoma, in HeLa cells and in pre-
malignant conditions such as familial adenomatous 
polyposis and polyposis coli13.14.15. COX-2 expression is 
elevated in up to 85 - 90% of human colorectal 
carcinoma cases and in up to 40 - 50% of colonic 
adenomas '6 In a recent publication, it was reported that 
cells with over expression of COX-2 demonstrated 
resistance to apoptosis with increased cell adhesion to 
extra cellular matrix, hence explaining the possible 
tumour genesis 17 However, these effects were reversed 
with the administration of NSAIDs. 
The eJ5e ~f inhibitioi'l @f C:OX-2 ©md il'ldlJldi@i'il ~f 
«:IIp@ptosis 
This therapeutic aspect have been extensively studied in 
recent years. In 1991, a case controlled study reported 
that the use of NSAIDs reduced the risk of developing 
colon carcinoma by 50%18. In individuals with 
colorectal carcinoma, a similar (40 - 50%) decrease in 
terms of mortality was demonstrated with the 
administration of NSAIDsI9. However, this protective 
effect does not seem to continue with cessation of 
therapy. The administration of sulindac, a selective. 
COX-2 inhibitor not only brought the levels of COX-2 
and prostaglandins formation to baseline but also 
restored normal levels of apoptosis l5 . Another study 
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showed that administration of nimesulide, a selective 
COX-2 inhibitor, induced apoptosis in HeLa cells. The 
levels of cell death were comparable to that induced by 
cyclohexamide, a potent inducer of apoptosisl4. In cases 
of familial adenomatous polyposis, the use of NSAIDs 
results not only in regression of the polypoid size, but 
also in the number of polypsll. 
However, how apoptosis is achieved in these studies still 
remains unclear. Some have postulated that NSAIDs 
actually induce tissue transglutaminases, a hallmark in 
apoptosis resulting in cytoskeletal crosslinking lO • Cells 
in the Go phase are protected from cell death by p20 and 
other quiescence-specific proteins. The use of NSAIDs 
down regulates the expression of p20, an effect that 
enhances apoptosis 'o . There are also suggestions that 
COX-2 and local mediators may function in signal 
transduction pathways leading eventually to the 
ultimate goal of apoptosis, containing p53 and bcl-2 
gene. However, a recent study suggested that apoptosis 
due to administration of NSAIDs involves a pathway 
that is independent of cyclooxygenase inhibition, cell 
cycle arrest and p53 induction20 • Another paper has 
suggested that with the use of non-steroidals, the levels 
of arachidonic acid is elevated as the prostanoid 
biosynthesis is halted. This dramatic increase in 
arachidonic acid in turn stimulates the conversion of 
sphingomyelin into ceramide, a known mediator of 
apoptosis2l . 
A number of malignant and pre-malignant conditions 
demonstrate over expression of COX-2. In these tumours 
or cell models, the use of non-steroidal anti-inflammatory 
agents can actually result in apoptosis, often with classical 
features. Although the exact mechanism by which 
apoptosis is achieved has yet to be determined, the 
significant decrease in terms of patient risk and mortality 
rate in cases of colon and colorectal carcinoma strongly 
indicates that specific/selective COX-2 inhibitors such as 
sulindac, meloxicam, NS 398 and nimesulide have a 
potential role in individuals with a high risk of colorectal 
carcinoma such as those with familial adenosis polyposis 
and those with a history of adenomas. 
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